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The probiotic approach represents an alternative strategy in the prevention and treatment of infectious
diseases, not only at the intestinal level but also at other sites of the body where the microbiota plays a role
in the maintenance of physiological homeostasis. In this context, we evaluated in vitro the potential abilities of
probiotic and dairy bacteria in controlling Streptococcus pyogenes infections at the pharyngeal level. Initially, we
analyzed bacterial adhesion to FaDu hypopharyngeal carcinoma cells and the ability to antagonize S. pyogenes
on FaDu cell layers and HaCat keratinocytes. Due to its promising adhesive and antagonistic features, we
studied the dairy strain Lactobacillus helveticus MIMLh5, also through in vitro immunological experiments.
First, we performed quantification of several cytokines and measurement of NF-B activation in FaDu cells.
MIMLh5 efficiently reduced the induction of interleukin-6 (IL-6), IL-8, and tumor necrosis factor alpha
(TNF-), in a dose-dependent manner. After stimulation of cells with IL-1, active NF-B was still markedly
lowered. Nevertheless, we observed an increased secretion of IL-6, gamma interferon (IFN-), and granulocyte-
macrophage colony-stimulating factor (GM-CSF) under these conditions. These effects were associated with
the ability of MIMLh5 to enhance the expression of the heat shock protein coding gene hsp70. In addition,
MIMLh5 increased the GM-CSF/G-CSF ratio. This is compatible with a switch of the immune response toward
a TH1 pathway, as supported by our observation that MIMLh5, once in contact with bone marrow-derived
dendritic cells, triggered the secretion of TNF- and IL-2. In conclusion, we propose MIMLh5 as a potential
probiotic bacterium for the human pharynx, with promising antagonistic and immunomodulatory properties.
Over 100 years ago, the Nobel laureate Ilya Ilyich Metchni-
koff stated that “the dependence of the intestinal microbes on
the food makes it possible to adopt measures to modify the
flora in our bodies and to replace the harmful microbes by
useful microbes” (35). Metchnikoff, who proposed a link be-
tween lactic acid bacteria ingested with food and human
health, laid the foundations for what was later named the
probiotic approach.
In 2002, a joint FAO/WHO working group recommended
the adoption of the definition of probiotics as “live microor-
ganisms which when administered in adequate amounts confer
a health benefit on the host” (16). Today, probiotics have
become a multimillion dollar business, involving markets all
over the Western world, especially in Japan, Europe, and the
United States (28). Most of the probiotic products commer-
cialized to date have been intended for the gastrointestinal
tract and the gut microbiota. Nevertheless, more recently, new
categories of probiotic products have been developed, target-
ing different body compartments, such as the vaginal mucosa,
skin, or oral cavity (9, 31, 42).
The pharyngeal tract is a primary way of entrance into the
human body for many bacteria and viruses. The host can man-
age the presence of potentially harmful microorganisms in the
oropharyngeal cavity by means of the local immune system and
through the presence of the autochthonous microbiota. The
alteration of a proper human-microbiota mutualism in the oral
and pharyngeal mucosa can facilitate the onset of local infec-
tions (pharyngotonsillitis or rhinitis) or systemic diseases (pul-
monary and cardiac infections, rheumatic fever, septicemia, or
meningitis). The consumption of products containing probiotic
bacteria has been proposed as a strategy for preventing oral
pathogen colonization and proliferation. Probiotic lactic acid
bacteria, especially lactobacilli, are in fact known to play an
important role in the maintenance of human health at the
mucosal level, by stimulating the natural immunity and con-
tributing to the balance of the microbiota through competitive
exclusion of virulent microorganisms (13, 14, 28). Accordingly,
it has been demonstrated that the administration of lactobacilli
can reduce the oral carriage of potentially harmful streptococci
(1, 11). Furthermore, probiotics can prevent the occurrence or
decrease the severity of inflammatory diseases through inter-
action with the host’s immune system cells. As a matter of fact,
pathogenic and nonpathogenic microorganisms activate differ-
ent immunological pathways and intracellular signal transmis-
sion. In particular, commensal and probiotic bacteria can mod-
ulate the activation of important transmission factors, such as
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nuclear factor B (NF-B), and the production of different
cytokines (12, 14, 46).
In the oropharyngeal tract as well as in the intestine,
lymphoid tissue is copiously present and forms the mucosa-
associated lymphoreticular tissue (MALT). The two main
components of MALT, known as GALT (gut-associated lym-
phoreticular tissue) and NALT (nasopharynx-associated lym-
phoreticular tissue), are strictly linked, so the reciprocal ex-
change of immune system cells and molecules through blood
and lymph is possible. Therefore, the administration of se-
lected probiotic microorganisms can potentially affect host im-
mune responses at local and systemic levels, representing a
milder alternative to anti-inflammatory pharmaceutical thera-
pies.
In this study, we investigated dairy and probiotic bacteria in
vitro for their potential as probiotics for the pharyngeal mu-
cosa. As a consequence of the experiments carried out during
this research, we selected a bacterial strain, Lactobacillus hel-
veticus MIMLh5, which exhibits noticeable adhesion and an-
tagonistic activities on the FaDu human pharyngeal cell line
and shows promising immunomodulatory properties.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial strains used in this
study are listed in Table 1. Lactobacilli and Bacillus coagulans were cultivated in
MRS broth (Sharlau, Barcelona, Spain) supplemented with 0.05% L-cysteine–
HCl (cMRS) and incubated at 37°C overnight. Oral streptococci and Streptococ-
cus thermophilus were routinely grown overnight in M17 broth (Sharlau, Barce-
lona, Spain) supplemented with 2% lactose (LM17). Lactococci were grown
overnight in LM17 at 30°C. Bifidobacterium animalis subsp. lactis Bb12 was
grown under anaerobic conditions (Anaerocult A system; Merck, Darmstadt,
Germany) at 37°C in prereduced cMRS. Streptococcus pyogenes C11 (emm type
77; clinically isolated from a pharyngitis patient) was grown overnight at 37°C in
brain heart infusion (BHI) broth (Difco, Detroit, MI) supplemented with 0.3%
yeast extract.
Bacterial adhesion to FaDu cell layer. FaDu cells were grown in 3-cm petri
plates on microscope cover glasses until confluence was reached, as described
previously (23). Afterward, adhesion assays were performed as previously illus-
trated (22, 23).
Determination of antagonistic activity against Streptococcus pyogenes. Bacte-
rial antagonism was studied against the recombinant Streptococcus pyogenes
strain C11Luc, harboring the bioluminescence reporter vector pCSS945 (34).
Antagonism experiments were performed through exclusion and competition
assays according to the methods of Guglielmetti and collaborators (23), using
two different cell lines: FaDu (human pharynx carcinoma cell line; ATCC HTB-
43) and HaCat (human keratinocytes from a spontaneously immortalized, non-
tumorigenic cell line). Cell lines were routinely grown until confluence was
reached, as described previously (23). The bacterial cell concentration of an
overnight culture was determined microscopically by use of a Neubauer Im-
proved counting chamber (Marienfeld GmbH, Lauda-Königshofen, Germany).
Bacterial cells were washed with phosphate-buffered saline (PBS) and resus-
pended in the same buffer at the concentrations reported below. In the exclusion
assay, the cell layer was preincubated with 1 ml of a tester strain suspension (5 
108 cells ml1), followed by incubation with the indicator strain (2  108 cells
ml1 of S. pyogenes C11Luc). In exclusion experiments, we used a concentration
of 5  108 tester cells ml1 because this matched the plateau of a dose-response
curve prepared during the setup of the experiment by measuring the antagonistic
activity as a function of tester cell concentration (data not shown). Competition
consisted of coincubation of the same number of tester and indicator cells (2 
108 cells ml1). At the end of the incubation, the pH was monitored in order to
detect possible acidification. Bioluminescence was measured with a Victor 3
luminometer (PerkinElmer, Monza, Italy). Each tester strain was analyzed in
triplicate in at least two independent experiments. Unpaired Student’s t tests
were run to determine statistically significant differences.
Enzyme-linked immunosorbent assay (ELISA) measurement of cytokine pro-
duction by FaDu cells. Human pharyngeal carcinoma cells (FaDu) were grown in
24-well plates until confluence. Bacterial cells were resuspended in fresh antibi-
otic-free Eagle’s minimum essential medium (EMEM) containing 100 mM
HEPES (pH 7.4) and added to monolayers at a multiplicity of infection (MOI)
of about 1,000. EMEM-HEPES medium without bacterial cells was used as a
control. The same samples were also prepared by incubating bacteria and FaDu
cells in the presence of 2 ng ml1 of interleukin-1 (IL-1). After overnight
incubation at 37°C in the presence of 5% carbon dioxide, the supernatants were
collected and kept at 80°C. Finally, concentrations of different cytokines in the
supernatants were determined on a Bioplex array reader (Luminex 100; Bio-Rad
Laboratories, Hercules, CA), using a Bio-Plex human cytokine 17-plex panel
(Bio-Rad) according to the Bio-Plex human cytokine panel assay protocol (Bio-
Rad). The tested cytokines and corresponding detection limits were as follows:
IL-1, 0.3 pg ml1; IL-2, 0.2 pg ml1; IL-4, 0.1 pg ml1; IL-5, 0.3 pg ml1; IL-6,
0.2 pg ml1; IL-7, 0.3 pg ml1; IL-8, 0.3 pg ml1; IL-10, 0.2 pg ml1; IL-12 (p70),
0.4 pg ml1; IL-13, 0.3 pg ml1; IL-17, 0.5 pg ml1; granulocyte colony-stimu-
lating factor (G-CSF), 0.2 pg ml1; granulocyte-macrophage colony-stimulating
factor (GM-CSF), 1.1 pg ml1; gamma interferon (IFN-), 2.6 pg ml1; mono-
cyte chemotactic protein 1 (MCP-1), 0.8 pg ml1; macrophage inflammatory
protein 1 (MIP-1), 0.6 pg ml1; and tumor necrosis factor alpha (TNF-), 0.6
pg ml1.
Measurement of NF-B activation in reporter FaDu cells. The FaDu cell line
was stably transfected with the luciferase reporter plasmid pNiFty2-Luc (Invivo-
Gen, LaboGen, Rho, Italy), as described previously (23). In pNiFty2-Luc, the
expression of an insect luciferase gene is induced by the active NF-B molecules
present in the cell. Recombinant FaDu cells were cultured using the same
protocol as that for nontransfected FaDu cells, in the presence of 50 g ml1 of
zeocin. In order to study the effect of bacterial cells on NF-B activation,
recombinant FaDu cells were incubated for 4 h with bacteria resuspended in
EMEM broth supplemented with 100 mM HEPES (pH 7.4). After incubation,
the samples were treated as described by Guglielmetti et al. (23). Finally, ATP
and D-luciferin were added to the samples, and the emitted bioluminescence was
immediately recorded with a Victor 3 luminometer (PerkinElmer, Monza, Italy).
In a different set of experiments, recombinant FaDu cells were simultaneously
stimulated with IL-1 (2 ng ml1). All strains were analyzed in duplicate in at
least three independent experiments for each MOI. Unpaired Student’s t test was
run to determine statistically significant differences.
TABLE 1. Bacteria included in the study
Species Strain Source Reference
Bacillus coagulans NF4 Probiotic commercial strain
Bifidobacterium animalis subsp. lactis Bb12 Probiotic commercial strain 25
Lactobacillus acidophilus La-5 Probiotic commercial strain 25
Lactobacillus casei Shirota Probiotic commercial strain 25
Lactobacillus helveticus MIMLh5 Dairy natural starter 21
Lactobacillus rhamnosus GG Probiotic commercial strain 25
Lactococcus lactis subsp. cremoris Viili Finnish fermented milk 27
Streptococcus oralis ST4 Human pharynx 23
Streptococcus pyogenes C11 Human pharyngeal pathogen
Streptococcus salivarius K12 BLIS K12 Throat Guard 47
ST3 Human pharynx 23
Streptococcus thermophilus DSM20617T Yogurt (species type strain) 2
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Transcriptional analysis of heat shock genes in FaDu cells. FaDu cells were
cultured until confluence, using the same protocol as that described above. After
growth, the FaDu cell layer was detached by trypsinization, and cells were
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) at a concentra-
tion of 250,000 cells ml1 in the presence of 100 mM HEPES (pH 7.4). Subse-
quently, 50 l of tester bacterial suspension, containing 2  109 or 2  108 cells,
was added to 450 l of FaDu cell suspension, resulting in an MOI of about 1,000
or 100, respectively. The analysis was performed at baseline and after the addi-
tion of 2 ng ml1 of IL-1. After incubation at 37°C for 4 h, cells were recovered
by centrifugation (2,000  g for 4 min at 4°C), and the supernatant was discarded.
Total RNA was isolated from a FaDu cellular pellet by use of iScript RT-qPCR
sample preparation reagent (Bio-Rad Laboratories, Milano, Italy) following the
manufacturer’s protocol. RNA was used for reverse transcription with an iScript
cDNA synthesis kit (Bio-Rad Laboratories) according to the manufacturer’s
instructions. Real-time quantitative PCR (qPCR) was carried out using
EvaGreen PCR master mix (Bio-Rad Laboratories) and 6.5 l of 1:40-diluted
cDNA reaction mix. The qPCRs were performed in triplicate and run on a
CFX96 thermocycler (Bio-Rad Laboratories). Data were recorded as threshold
cycles (CT) and expressed as means  standard deviations, computed using
Bio-Rad CFX Manager software and expressed as normalized expression
(		CT)  standard errors of the means. The following primers (5) were used in





; hsp70 forward, 5
-GCGACCT
GAACAAGAGCATC-3
; and hsp70 reverse, 5
-GAGCTTGCCCTTGAGACC
C-3
. The expression levels of the heat shock genes hsp27 and hsp70 were
normalized using genes coding for -actin (ACTB) (forward primer, 5
-CTGG
AACGGTGAAGGTGACA-3
; and reverse primer, 5
-AAGGGACTTCCTGT
AACAATGCA-3
) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(forward primer, 5
-GGAGTCCACTGGCGTCTTCAC-3
; and reverse primer,
5
-GAGGCATTGCTGATGATCTTGAGG-3
) as reference housekeeping
genes, because these genes were recently shown to be the most stable in an
epithelial cell line (40). The qPCR cycle program used was the following: initial
denaturation at 95°C for 3 min, followed by 40 cycles of denaturation at 95°C for
10 s, annealing at 55.9°C for 30 s, and extension at 72°C for 40 s. Finally, melting
curve analysis from 65 to 95°C was also performed. For each condition, the
measurements were carried out in triplicate with cDNAs synthesized from two
independent RNA samples.
Study of activation of BMDCs. Dendritic cells were obtained in vitro from
bone marrow hematopoietic precursors isolated from C57BL/6 mouse femurs as
described previously (18). In brief, hematopoietic precursors were recovered
from mouse femoral bone marrow and resuspended in conditioned medium
(complete medium supplemented with 10% of the growth supernatant of GM-
CSF-transduced B16 cells). About 7  106 cells were plated in 100-mm suspen-
sion plates. The proportion of CD11c cells (corresponding to dendritic cells)
was monitored periodically by flow cytometry until it reached 90% (ca. 10 days).
The bone marrow-derived dendritic cells (BMDCs) were then used for bacterial
activation assays. On the day of bacterial infection, BMDCs were plated at a
concentration of 0.5 million per ml in 96-well plates (105 cells/well). After 1 h,
BMDCs were incubated with four different concentrations of bacterial cells for
2 h, washed with saline, resuspended in a culture medium containing penicillin G,
streptomycin, tetracycline, and gentamicin, and incubated overnight. Finally,
IL-2 and TNF- in the supernatant were quantified by ELISA, using DuoSet kits
(R&D Systems, Minneapolis, MN).
Antibiotic susceptibility of Lactobacillus helveticus MIMLh5. The inhibitory
concentrations of antimicrobial agents were determined by broth microdilution
assay as described elsewhere (23), using the following concentration ranges: for
ampicillin, chloramphenicol, erythromycin, oxytetracycline, and vancomycin, 1 to
16 g ml1; for gentamicin, 8 to 64 g ml1; and for kanamycin and strepto-
mycin, 16 to 128 g ml1. All antibiotics were from Sigma-Aldrich (Deisenhofen,
Germany). The experiments were performed by cultivating strain MIMLh5 in
cMRS broth.
RESULTS
Dairy and probiotic strains adhere differently to FaDu hu-
man pharyngeal cell line. Lactic acid bacterial strains were
tested for the ability to adhere to a FaDu epithelial cell layer.
Two dairy strains, Lactobacillus helveticus MIMLh5 and Lac-
tococcus lactis Viili, displayed adhesion properties comparable
to those of the oral bacterial strains Streptococcus salivarius
K12 and ST3, which were previously shown to adhere strongly
to FaDu cells (23). These four strains resulted in an adhesion
index (AdI; number of bacterial cells per 100 FaDu cells) of
2,500 (Fig. 1). Among probiotic bacteria, only Lactobacillus
rhamnosus GG displayed a good adhesion ability (AdI between
500 and 2,500). The other intestinal probiotics adhered poorly
(Lactobacillus acidophilus La-5) or negligibly (Bifidobacterium
animalis Bb12 and Lactobacillus casei Shirota).
Adhesive bacteria can efficiently antagonize Streptococcus
pyogenes on human epithelial cells. The ability of lactic acid
bacteria to antagonize S. pyogenes was investigated in vitro by
means of a three-component system consisting of the epithelial
cell layer, the indicator bioluminescent strain S. pyogenes
C11Luc, and the tester bacterium. In these experiments, we
measured the reduction of bioluminescence produced by S.
pyogenes C11Luc as an indication of the antagonistic activity
exerted by the tester strains.
Antagonism through exclusion was tested on two different
human cell lines, FaDu and HaCaT. Significant differences in
antagonistic exclusion were observed among the strains.
Roughly, with only a few exceptions, strains displaying good
adhesion properties antagonized S. pyogenes more efficiently
on human epithelial cells (Fig. 2). For instance, the nonadhe-
sive strains Bifidobacterium animalis Bb12 and Streptococcus
thermophilus DSM 20617T did not reduce the ability of recom-
binant S. pyogenes to produce light. In contrast, the strongly
adhesive strain Lactobacillus helveticus MIMLh5 was the most
active antagonist on both cell lines, with an average reduction
of bioluminescence of 55% on FaDu cells and 32% on HaCaT
cells (Fig. 2). Furthermore, strain MIMLh5 exhibited antago-
nistic exclusion comparable to that of the oral isolate Strepto-
coccus salivarius ST3 (40% reduction of bioluminescence on
FaDu cells and 24% reduction on HaCaT cells), which was
demonstrated in a previous study to be the best antagonist of
S. pyogenes among several oral bacteria, on the same epithelial
layers (23). In addition to MIMLh5 and ST3, the probiotic
strains L. rhamnosus GG and L. casei Shirota and the dairy
strain L. lactis subsp. cremoris Viili also displayed antagonistic
exclusion significantly stronger than that of the reference oral
probiotic strain S. salivarius K12 (Fig. 2).
Antagonism by competition was tested only on the FaDu cell
layer. In this experiment, all tested strains markedly inhibited
S. pyogenes bioluminescence (50% reduction), particularly L.
helveticus MIMLh5 (78% reduction) and S. salivarius strains
(ca. 80% reduction) (data not shown).
In successive experiments performed with strain MIMLh5,
we noted a possible correlation between the number of S.
pyogenes cells that adhered to the epithelial cell layer (deter-
mined by means of agar plate counts) and the bioluminescence
emitted by the sample (Fig. 3). This result suggests that a
determinant of the modification of light emission could be the
number of recombinant S. pyogenes cells adhering to the epi-
thelial layer.
Immune responses by FaDu cells are importantly modu-
lated by L. helveticus MIMLh5. We carried out an investigation
of the potential immunomodulatory properties of the strain L.
helveticus MIMLh5 in comparison with the oral bacteria S.
salivarius K12 and Streptococcus oralis ST4. After overnight
incubation of a FaDu cell monolayer with selected bacteria, we
performed a quantification of 17 different secreted cytokines
by means of a Bio-Plex human cytokine 17-plex array system.
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All three bacterial strains induced a modification of the cyto-
kine production profile compared to that for FaDu cells incu-
bated under the same conditions without bacteria (Fig. 4).
Under baseline conditions, Streptococcus oralis ST4 was the
only strain to increase the secretion of IL-1 and to reduce that
of IFN-. It also reduced TNF- and increased GM-CSF lev-
els. The oral probiotic bacterium S. salivarius K12 predomi-
nantly decreased the secretion of IL-6, IL-8, TNF-, and G-
CSF, while it increased GM-CSF secretion (Fig. 4). Finally,
Lactobacillus helveticus MIMLh5 displayed the strongest abil-
ity to inhibit the secretion of IL-6 (from 78.1 to 5.5 pg ml1),
IL-8 (from 1,721 to 111 pg ml1), and G-CSF (from 3.5 to 0.2
pg ml1). Moreover, the strain MIMLh5 decreased TNF- and
enhanced GM-CSF levels (Fig. 4).
FIG. 1. Bacterial adhesion to FaDu epithelial cell layer. (A) Adhesion indexes (AdI; number of bacteria/100 FaDu cells). Adhesion values are
the means for two independent experiments conducted in duplicate. The variation between the replicates was less than 15%. (B) Cell layers
observed after Giemsa staining, using light microscopy. Bar, 8 m. N, FaDu cell nucleus, indicated once for each layer.
FIG. 2. Antagonistic exclusion activities of dairy and probiotic bacteria against bioluminescent Streptococcus pyogenes C11Luc on FaDu
hypopharyngeal carcinoma cells (A) and HaCaT keratinocytes (B). Data are reported as percentages of variation in light emission relative to the
cell layer treated with PBS buffer only before incubation with S. pyogenes. Numerical results are given as arithmetic means  standard deviations.
Each sample was processed in triplicate in at least two independent experiments. Statistically significant differences compared to strain K12 were
determined by unpaired Student’s t test. **, P  0.001; *, P  0.05.
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We also performed the same experiments by stimulating
FaDu cells with 2 ng ml1 of the proinflammatory cytokine
IL-1 (Fig. 4). With respect to baseline, the presence of IL-1
induced a drastic change in cytokine profile for strain
MIMLh5. In fact, several cytokines which were considerably
reduced by L. helveticus MIMLh5 at baseline showed increased
secretion when FaDu cells were incubated with MIMLh5 in
the presence of IL-1. The modification of MIMLh5’s effect in
the presence of IL-1 was particularly evident for the cytokines
IL-6, IL-8, G-CSF, IFN-, MIP-1, and TNF-. This trend also
emerged for the other two tested strains, but to a much lesser
extent. Specifically, the presence of IL-1 increased the secre-
tion of MCP-1, MIP-1, and TNF- for S. salivarius K12 and
that of IFN-, MCP-1, and TNF- for S. oralis ST4 (Fig. 4).
Afterward, we explored the immunomodulatory properties
of selected lactic acid bacteria by testing the effect of the
microorganisms on NF-B activation. This study was done
through the use of a reporter cell line obtained by transfecting
FaDu cells with a luciferase reporter vector induced by active
NF-B. At baseline, L. helveticus MIMLh5 was the only strain
that decreased the NF-B-dependent production of biolumi-
nescence. In contrast, S. oralis ST4 showed a stimulatory effect,
while S. salivarius K12 did not significantly affect NF-B acti-
vation (Fig. 5A). Furthermore, we found that the inhibitory
effect of strain MIMLh5 on NF-B activation was not signifi-
cantly affected by the presence of an equal number of S. sali-
varius K12 or S. oralis ST4 cells during incubation with FaDu
cells (Fig. 5A).
The effect of bacterial strains on NF-B was also assessed
during stimulation of FaDu cells with IL-1. The addition of 2
ng ml1 of IL-1 to recombinant FaDu cells induced an ap-
proximately 2-fold increase in bioluminescence, indicating a
higher level of activation of NF-B. S. salivarius K12 and S.
oralis ST4 partially inhibited the IL-1-dependent increase in
bioluminescence, but only at the highest MOI tested (39% and
30% reductions, respectively). Nevertheless, only strain L. hel-
veticus MIMLh5 strongly inhibited NF-B activation in the
presence of IL-1 in a concentration-dependent manner (84%
reduction at an MOI of 1,000 and 61% reduction at an MOI of
100) (Fig. 5B).
L. helveticus MIMLh5 triggers a heat shock response in
IL-1-treated FaDu cells. According to the literature, the up-
regulation of proinflammatory cytokines in FaDu cells treated
with L. helveticus MIMLh5 in the presence of IL-1 can be
explained by the induction of a heat shock response (43). For
this reason, reverse transcription-qPCR was used to assess the
effect of MIMLh5 on the expression by FaDu cells of two genes
involved in the heat shock response (hsp27 and hsp70). At
baseline, mRNA levels of hsp27 and hsp70 did not change
significantly when MIMLh5 was coincubated with FaDu cells
at MOIs of 100 and 1,000. The same experiment was also
performed after addition of 2 ng ml1 of IL-1 before the
incubation of FaDu cells with MIMLh5. Under this condition,
the expression of hsp27 also stayed unaltered. In contrast,
coincubation of MIMLh5 with IL-1-stimulated FaDu cells
showed 4.3- and 4.2-fold higher hsp70 mRNA expression at
MOIs of 100 and 1,000, respectively (data not shown).
L. helveticus MIMLh5 can trigger the secretion of IL-2 by
DCs in vitro. Dendritic cells (DCs) are known to be key regu-
lators of the immune system. Their capacities to recognize
microorganisms and to start an appropriate immune response
are broadly described. Once activated, DCs produce many
soluble and cell surface molecules able to initiate and direct
the activity of innate and adaptive lymphocytes. Among the
molecules released by DCs upon their activation, proinflam-
matory (such as TNF- and IL-6) and immunomodulatory
(such as IL-12, IL-2, and transforming growth factor beta
[TGF-]) cytokines play a key role in this process.
To evaluate the capacity of the selected bacteria to interact
with and activate DCs, BMDCs were incubated with different
concentrations of L. helveticus MIMLh5, L. acidophilus La-5,
and Bacillus coagulans NF4. Strain La-5 was introduced in this
experiment as a positive control, because it has been shown
that L. acidophilus can significantly upregulate activating sur-
face markers on DCs (53). Furthermore, Escherichia coli-de-
rived lipopolysaccharide (LPS), since previously described to
be a potent regulator of DC immunoregulatory functions, was
added as a positive control (52). On the other hand, we used
Bacillus coagulans NF4 as a negative control, because this
strain did not show any immunomodulatory properties in pre-
vious experiments carried out in our laboratory (unpublished
data). Supernatants from activated BMDCs were collected and
analyzed by ELISA for the presence of TNF- and IL-2 24 h
after incubation with bacterial cells. Strains MIMLh5 and La-5
effectively induced the production of both cytokines at all
MOIs tested, while NF4, as expected, did not (Fig. 6). In
particular, while the effect of La-5 on IL-2 and TNF- secre-
tion was strictly dose dependent, the production of these cy-
tokines by DCs stimulated with MIMLh5 was already high at
the lowest MOI (Fig. 6).
Lactobacillus helveticus MIMLh5 is susceptible to most an-
tibiotics. Bearing in mind the possible use of Lactobacillus
FIG. 3. Antagonistic exclusion activity against bioluminescent
Streptococcus pyogenes C11Luc on FaDu hypopharyngeal carcinoma
cells. (A) Light emission curves registered after addition of D-luciferin.
RLU, relative luminescence units. (B) Percentage variation in light
emission relative to the cell layer treated with PBS buffer only before
incubation with S. pyogenes. Results are given as arithmetic means 
standard deviations calculated for three replicates. (C) Agar plate
counts of S. pyogenes cells that remained adhered after treatment of
the FaDu cell layer with MIMLh5, K12, or PBS (control).
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helveticus MIMLh5 as a probiotic, we preliminarily assessed
the safety of this strain by studying its antibiotic resistance with
reference to the European Food Safety Authority (EFSA)
breakpoints for Lactobacillus helveticus (15). MIMLh5 was
found to be sensitive to all tested antibiotics except for kana-
mycin (Table 2). However, it appears reasonable to consider
the resistance to kanamycin as intrinsic and not related to a
specific gene. It is known, in fact, that several lactobacilli have
a high level of natural resistance to kanamycin and other ami-
noglycosidic antibiotics (7).
DISCUSSION
In the current study, we characterized the in vitro properties
of lactic acid bacteria in order to establish their possible use as
probiotics for the pharyngeal mucosa. Among the features
required for a potential probiotic, the guidelines proposed by
the Food and Agricultural Organization (FAO) emphasize the
need for a correct taxonomic identification and safety status of
the microorganism (16). For this reason, we focused our at-
tention on bacterial strains of dairy and probiotic origin al-
ready present on the market, which in general can be deemed
safe. In detail, strains MIMLh5, Viili, and DSM 20617T are
used as starters in the production of Grana Padano cheese,
Finnish fermented milk, and yogurt, respectively. The strains
Bifidobacterium animalis subsp. lactis Bb12, Lactobacillus
acidophilus La-5, Lactobacillus rhamnosus GG, and Lactoba-
cillus casei Shirota are among the most widespread probiotic
strains in Western countries. Certain properties of these strains
have been compared to those of Streptococcus salivarius K12,
the only probiotic bacterium specifically commercialized as a
probiotic for the pharyngeal mucosa to date (BLIS K12 Throat
Guard [47]). Finally, we also included in the study two strains,
Streptococcus salivarius ST3 and Streptococcus oralis ST4, iso-
lated from human pharyngeal mucosa and recently studied in
a project focusing on the selection of oral bacteria for use as
probiotics (23).
The first probiotic property that we considered was adhesion
FIG. 4. Histograms showing selected cytokines whose secretion changed after overnight incubation of the FaDu cell layer with bacterial cells
(2  108 cells ml1), as determined using Bio-Plex assay. The values are the means for two independent experiments conducted in duplicate. The
error bars indicate standard deviations.
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to the host’s target epithelium. The ability of commensals and
probiotics to bind human mucosa has pivotal importance be-
cause it can promote colonization and sustain host epithelium-
bacterium cross talk (33). Our experiment showed that two
dairy strains, L. helveticus MIMLh5 and L. lactis Viili, can
adhere to the FaDu pharyngeal epithelial cell line comparably
to the oral probiotic bacterium S. salivarius K12, which is
known to be able to colonize the oropharyngeal mucosa after
oral administration (24).
Streptococcus pyogenes (group A streptococci [GAS]) causes
approximately 15 to 30% of pediatric sore throat cases (8), and
it is the etiological agent of skin and soft tissue infections,
glomerulonephritis, and acute rheumatic fever. The oral ad-
ministration of probiotic bacteria could be a prophylactic strat-
egy effective to reduce the transmission of GAS in the com-
munity (49). For this reason, we tested the ability of probiotic
bacteria to antagonize GAS on in vitro epithelial layers. Since
the oral cavity contains several types of surface epithelia, in-
cluding keratinized and nonkeratinized epithelia, we also in-
FIG. 5. Modulation of light emission expressed by FaDu cells stably transfected with an NF-B/luciferase reporter vector and incubated with
selected bacterial strains, at baseline (A) or stimulated with 2 ng ml1 of IL-1 (B). Luciferase activity is expressed as the percent change in light
emission (relative light units [RLU]), assuming the control without IL-1 to be 100%. Control, FaDu cell layers incubated without bacterial cells.
Footnote a, bacterial strains employed at an MOI of 1,000 each (number of bacterial cells per FaDu cell). The values are the means ( standard
deviations) for at least three independent experiments conducted in duplicate. Asterisks indicate statistically significant differences compared to
the corresponding control (**, P  0.001; *, P  0.05).
FIG. 6. Production of TNF- and IL-2 by BMDCs after 24 h of
stimulation with the indicated bacteria. MOI, multiplicity of infection
(number of bacterial cells per BMDC); LPS, lipopolysaccharide from
Escherichia coli (positive control); MIMLh5, Lactobacillus helveticus
MIMLh5; La-5, Lactobacillus acidophilus La-5; NF4, Bacillus coagu-
lans NF4 (negative control).
TABLE 2. Antibiotic sensitivities of Lactobacillus helveticus
MIMLh5




Chloramphenicol 4 and 1 4
Erythromycin 1 1
Gentamicina 16 and 8 16
Kanamycina 128 and 64 16
Oxytetracycline 4 and 1 4
Streptomycina 16 16
Vancomycin 1 2
a Possible interference of the growth medium has been reported (15).
b Microbiological breakpoints categorizing Lactobacillus helveticus as resistant
according to EFSA guidelines (15).
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cluded in the experimentation, besides FaDu cells, the HaCat
cell line, which resembles many characteristics of human
keratinocytes (10). The dairy strain L. helveticus MIMLh5,
which adhered as well as or better than all the other bacteria
on the FaDu cell layer, displayed the best antagonizing activity
against GAS on both cell lines. Microscopic observation (Fig.
1) and plate counts of adhered GAS after antagonism assays
(Fig. 3) seemed to suggest that a main mechanism of antago-
nism of MIMLh5 against GAS on human in vitro epithelia
could be competition for the adhesion sites.
Due to its promising properties, L. helveticus MIMLh5 was
chosen for the following experiments focusing on the in vitro
characterization of the host-bacterium cross talk from an im-
munological point of view. Many beneficial claims have been
attributed to probiotic supplementation for human health, es-
pecially for effects on the systemic and mucosal immunity. It
has in fact been demonstrated that probiotics, particularly lac-
tobacilli, can modulate the innate or adaptive immune re-
sponse (17, 29).
In our study, we investigated the immunomodulatory prop-
erties of the selected strain, L. helveticus MIMLh5, in contact
with FaDu cells by the quantification of 17 different secreted
cytokines and through the measurement of NF-B activation.
We also included in the study strain S. oralis ST4, a character-
istic oral bacterium, and S. salivarius K12, a commercial oral
probiotic which was recently demonstrated to induce in vitro
anti-inflammatory responses in epithelial cells (14).
Under baseline conditions, we found that strains K12 and
MIMLh5 reduced IL-8, IL-6, and TNF- secretion. The re-
duced secretion of these cytokines promoted by strain
MIMLh5 in FaDu cells can potentially be explained by the
concomitant inhibition of NF-B activation found in our ex-
periments. In fact, the transcriptional regulator NF-B is a
transcriptional inducer of IL-8 and several other cytokines and
is a therapeutic target in a wide range of human (auto)inflam-
matory diseases (51). It is well known that the mechanism of
action of many anti-inflammatory compounds, including salic-
ylate and corticosteroids, involves NF-B inhibition (4, 30).
Furthermore, intestinal and/or probiotic microorganisms have
also been proposed to exert their immunomodulatory activity
through the modulation of NF-B signaling and the subse-
quent reduction of IL-8 production (46).
Interestingly, the cell concentration-dependent ability of L.
helveticus MIMLh5 to reduce NF-B activation was particu-
larly significant after stimulation by the proinflammatory cyto-
kine IL-1. Nevertheless, under this condition, we observed a
simultaneous increase of the secretion of several cytokines,
such as IL-6, G-CSF, GM-CSF, IFN-, MCP-1, MIP-1, and
TNF-. A possible explanation can be found in a recent study
in which Lactobacillus paracasei was shown to potentiate the
effect of IL-1 on IL-6 production in cultured enterocytes by
inducing a heat shock response (43). Accordingly, in our study,
coincubation of FaDu cells with L. helveticus MIMLh5 in-
creased the expression level of the heat shock protein coding
gene hsp70 about 4-fold when IL-1 was present. The induc-
tion of heat shock proteins such as HSP27 and HSP70 has an
inhibitory effect on the degradation of the inhibitory protein
IB and, consequently, attenuates NF-B activation (5). Si-
multaneously, it is also known that the heat shock response
upregulates basal and IL-1-stimulated IL-6 production in hu-
man enterocytes (39, 41). It can be hypothesized, therefore,
that transcription factors other than NF-B become important
for the regulation of several cytokine genes during the heat
shock response potentially induced by MIMLh5. In addition,
previous studies suggested that heat shock proteins may pro-
tect mRNAs from degradation (26, 32, 36, 48). We can spec-
ulate that a similar mechanism can protect the transcripts of
cytokines from degradation as well, resulting in their enhanced
synthesis and secretion.
Particular attention should be given to IL-6, a pleiotropic
cytokine abundantly produced at the mucosal level, which is
generally associated with proinflammatory effects (38) but can
also have anti-inflammatory properties (50). IL-6, in fact, has
been shown to exert protective effects during inflammation
caused by injury and sepsis (6, 45). In our experiments,
MIMLh5 modulated IL-6 secretion differently, depending on
the context: IL-6 secretion was drastically inhibited at baseline,
while it was enhanced in the presence of IL-1. In light of the
multiple important biological roles of IL-6, locally in the mu-
cosa and systemically (38, 50), the ability of MIMLh5 to mod-
ulate mucosal IL-6 production may have important clinical
implications.
We found that MIMLh5 at baseline can inhibit G-CSF se-
cretion, concomitantly with the stimulation of GM-CSF. My-
eloid DCs, which drive the T-cell response to a TH1 type,
require the presence of GM-CSF for survival, in contrast to
lymphoid DCs, which induce a TH2 response and are mobi-
lized by G-CSF (3, 37, 44). A systemic and local increase of the
GM-CSF/G-CSF ratio, for instance, has been correlated with a
TH1-dominating response and good clinical status in cystic
fibrosis patients (37). In order to ascertain whether MIMLh5
can switch the immune response to a TH1 response, we tested
the ability of this bacterium to activate DCs. DCs are special
leukocytes particularly frequent in tissues forming an interface
with the external environment, for instance, in mucosal lym-
phoid organs and tonsil crypts, where they perform a sentinel
function and can recruit and activate cells of the innate im-
mune system, such as natural killer (NK) cells (20).
Activated DCs are required for NK cell priming. It has been
demonstrated that the capacity of NK cells to produce IFN-,
which is necessary for TH1 polarization, is strictly dependent
upon IL-2 derived from DCs (19, 20). In our study, the stim-
ulation of mouse bone marrow-derived DCs with MIMLh5
resulted in an enhanced production of IL-2 and TNF-, con-
firming that this bacterium could potentially skew the immune
response toward the TH1 phenotype, thus having a potential
immunomodulatory role at the systemic level (Fig. 6).
In conclusion, during this research we evaluated in vitro the
potential health-promoting properties at the pharyngeal level
of some of the most common commercial probiotic bacteria,
including two oral streptococci and three dairy microorgan-
isms. According to this study, we propose a dairy bacterium, L.
helveticus MIMLh5, as a potential pharyngeal probiotic be-
cause of its ability to adhere to human epithelial cell lines and
to efficiently antagonize GAS on these cells. Furthermore, L.
helveticus MIMLh5 appears to be a promising probable mod-
ulator of the immune system which is able to reduce NF-B
activation, to influence cytokine secretion at the epithelial
level, and potentially to skew the immune system toward a TH1
response. A new study is now in progress to identify the bac-
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terial cell components involved in the immunomodulatory
properties of L. helveticus MIMLh5.
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